BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Sasaki T, Isayama H, Nakai Y, Ito Y, Yasuda I, Toda N, Yagioka H, Matsubara S, Hanada K, Maguchi H, Kamada H, Hasebe O, Mukai T, Okabe Y, Maetani I, Koike K. Treatment outcomes of chemotherapy between unresectable and recurrent biliary tract cancer. World J Gastroenterol 2014; 20(48): 18452-18457 [PMID: 25561816 DOI: 10.3748/wjg.v20.i48.18452] [Cited by in CrossRef: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
Number Citing Articles
1 Seo S, Sudo T, Inoue M, Tashiro H. Stage IVB Incidental Gallbladder Carcinoma with R0 Resection Achieved by Multidisciplinary Treatment Including Three Surgeries. Jpn J Gastroenterol Surg, Nihon Shokaki Geka Gakkai zasshi 2019;52:166-175. [DOI: 10.5833/jjgs.2018.0077] [Reference Citation Analysis]
2 Kobayashi S, Ueno M, Sugimori K, Morizane C, Kojima Y, Irie K, Goda Y, Morimoto M, Ohkawa S. Phase II study of fixed dose-rate gemcitabine plus S-1 as a second-line treatment for advanced biliary tract cancer. Cancer Chemother Pharmacol 2017;80:1189-96. [PMID: 29071413 DOI: 10.1007/s00280-017-3461-z] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.2] [Reference Citation Analysis]
3 Takahara N, Isayama H, Nakai Y, Sasaki T, Ishigaki K, Saito K, Akiyama D, Uchino R, Mizuno S, Yagioka H, Kogure H, Togawa O, Matsubara S, Ito Y, Toda N, Tada M, Koike K. Gemcitabine and S-1 versus gemcitabine and cisplatin treatment in patients with advanced biliary tract cancer: a multicenter retrospective study. Invest New Drugs 2017;35:269-76. [PMID: 28124197 DOI: 10.1007/s10637-017-0430-7] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.4] [Reference Citation Analysis]
4 Li H, Zhang Z, Zhou Z, Ding X, Zhou G. Optimal combination of gemcitabine, sorafenib, and S-1 shows increased efficacy in treating cholangiocarcinoma in vitro and in vivo. Anti-Cancer Drugs 2016;27:600-8. [DOI: 10.1097/cad.0000000000000365] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]